First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Healthy

Interventions

BIOLOGICAL

BCD-147

Bispecific anti-HER2 monoclonal antibody

Trial Locations (1)

"Medical Center Eco-Safety", Saint Petersburg